Canada Pension Plan Investment Board Invests $88,000 in LivaNova PLC (NASDAQ:LIVN)

Canada Pension Plan Investment Board acquired a new position in LivaNova PLC (NASDAQ:LIVN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,600 shares of the company’s stock, valued at approximately $88,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Primecap Management Co. CA boosted its stake in LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock worth $327,889,000 after buying an additional 44,049 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of LivaNova by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock valued at $102,537,000 after acquiring an additional 62,480 shares in the last quarter. Greenlight Capital Inc. boosted its position in shares of LivaNova by 3.5% during the 4th quarter. Greenlight Capital Inc. now owns 1,229,316 shares of the company’s stock valued at $63,605,000 after acquiring an additional 42,040 shares in the last quarter. Magnetar Financial LLC boosted its position in shares of LivaNova by 24.5% during the 1st quarter. Magnetar Financial LLC now owns 753,338 shares of the company’s stock valued at $42,142,000 after acquiring an additional 148,178 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of LivaNova by 4.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 506,105 shares of the company’s stock valued at $27,745,000 after acquiring an additional 20,275 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on LIVN shares. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Stifel Nicolaus lifted their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Robert W. Baird upgraded shares of LivaNova from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $55.00 to $66.00 in a research report on Tuesday, September 17th. Finally, Needham & Company LLC lifted their target price on shares of LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $70.80.

LivaNova Trading Up 0.4 %

Shares of LIVN stock opened at $52.52 on Monday. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47. The company has a market capitalization of $2.84 billion, a P/E ratio of -87.53 and a beta of 1.00. The firm has a 50-day moving average price of $48.71 and a 200 day moving average price of $53.34. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The firm had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. Research analysts forecast that LivaNova PLC will post 2.58 earnings per share for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.